Fuqiang Zhao1, Denise Welsh1,
Mangay Williams1, Alexandre Coimbra1, Mark O. Urban2,
Richard Hargreaves2, Jeffrey Evelhoch1, Donald S.
Williams1
1Imaging Department, Merck Research
Laboratories, West Point, PA, United States; 2Neuroscience
Department, Merck Research Laboratories, West Point, PA, United States
To
validate the fMRI signals in the spinal cord and the brain of rats induced by
noxious stimulation as a pain biomarker, and to determine its utility in
elucidation of mechanisms of action of analgesics, the effect of
buprenorphine (BPN), a partial -opioid agonist, on pain fMRI signals was
investigated. The pain fMRI signals in the caudate putamen and thalamus
region were totally suppressed, while those in spinal cord, cerebellum,
thalamic relay of somatosensory pathway, and primary somatosensory cortex
were only partially (if at all) suppressed. Such a suppression pattern is
consistent with the density of opioid receptor distribution in brain,
supporting the idea that fMRI can provide anatomical action sites of the
analgesics, which should help to understand their mechanisms of action.